POPULAR SECTIONS

TREATMENT REGIMENS DRUG INFO MEDICAL CALCULATORS PUBLISHERS ALLIANCE VIDEOS CME

FDA: First Generic Version of Cancer Drug Doxil Approved

Share this article:
FDA approves new opioid-addiction drug
FDA approves new opioid-addiction drug

(HealthDay News) -- The first generic version of the cancer drug Doxil (doxorubicin hydrochloride liposome injection) has been approved by the U.S. Food and Drug Administration, which says the action should help relieve shortages of the brand-name medication.

Doxil is on the agency's drug shortage list. The list empowers the FDA's Office of Generic Drugs to grant priority review to generic equivalents, the agency said Monday in a news release.

Noting that generics were of the same quality and strength as the original drugs, the FDA said: "Generic manufacturing and packaging sites must pass the same quality standards as those of brand-name drugs."

Generic Doxil will be produced by Sun Pharma Global FZE in 20 milligram and 50 milligram vials. The brand-name drug is produced by Janssen Pharmaceuticals.

More Information

Share this article:

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in General Oncology News

Many Newly Approved Anticancer Drugs Increase Toxicity

Many Newly Approved Anticancer Drugs Increase Toxicity

Managing toxicity costs higher for treatment with less-specific targeted agents and chemotherapies.

For HER2-Positive Uterine Serous Carcinoma, Afatinib May Be Effective

For HER2-Positive Uterine Serous Carcinoma, Afatinib May Be ...

Afatinib caused uterine serous carcinoma tumors to shrink.

New Analyses for Phase 3 Lenvatinib SELECT Study

New Analyses for Phase 3 Lenvatinib SELECT Study

Baseline angiopoietin-2 may be able to be used as a predictive factor for lenvatinib response in endocrine cancer.